Reaction
Gallbladder Enlargement reporting signals
As of the last recalculation, Gallbladder Enlargement appears in 1,048 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is PEGASPARGASE (PRR 19.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pegaspargase | 12 | 19.7 | 19.7 |
| Teduglutide | 12 | 17.9 | 17.9 |
| Mercaptopurine | 15 | 17.4 | 17.4 |
| Ursodiol | 16 | 14.8 | 14.8 |
| Ursosiol | 14 | 14.5 | 14.5 |
| Vincristine Sulfate | 17 | 11.7 | 11.7 |
| Drospirenone And Ethinyl Estradiol | 25 | 11.5 | 11.5 |
| Lanreotide Acetate | 4 | 10.2 | 10.2 |
| Eculizumab | 20 | 7.4 | 7.4 |
| Lenvatinib | 12 | 7.3 | 7.3 |
| Pembrolizumab | 35 | 6.8 | 6.8 |
| Remdesivir | 4 | 6.0 | 6.0 |
| Trifluridine And Tipiracil | 3 | 5.6 | 5.6 |
| Axitinib | 5 | 5.1 | 5.1 |
| Durvalumab | 5 | 4.9 | 4.9 |
| Tirzepatide | 26 | 3.3 | 3.3 |